An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

The requested reference [9f3ff913d86c1351de72a85dad93841882f371de] no longer exists in our database. It has been replaced by the current reference: [ea423ac2b8c8a8810076fb8c5ce35845cd9dc4c2]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.
Epistemonikos ID: 2cc99aad29c78e55274a0d760007379dec9ac89f
First added on: Mar 31, 2022